Bevacizumab is largely used in colorectal cancer patients. Postsurgical healing complications have been described for patients following treatment with Bevacizumab. We report three cases of spontaneous intestinal perforation following infusion of Bevacizumab. From January 2002 through October 2010, Bevacizumab was delivered in 143 patients. Spontaneous intestinal perforation occurred in 3 cases (2.1 %). Bevacizumab may result in severe complications. Therefore, it is important to consider every patient treated with Bevacizumab at risk for life-threatening gastro-intestinal complications.
Infusion of bevacizumab increases the risk of intestinal perforation: results on a series of 143 patients consecutively treated
Borzomati D;Valeri S;Vincenzi B;Ripetti V;Coppola R
2013-01-01
Abstract
Bevacizumab is largely used in colorectal cancer patients. Postsurgical healing complications have been described for patients following treatment with Bevacizumab. We report three cases of spontaneous intestinal perforation following infusion of Bevacizumab. From January 2002 through October 2010, Bevacizumab was delivered in 143 patients. Spontaneous intestinal perforation occurred in 3 cases (2.1 %). Bevacizumab may result in severe complications. Therefore, it is important to consider every patient treated with Bevacizumab at risk for life-threatening gastro-intestinal complications.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.